AMRX — Amneal Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $5.17bn
- $7.69bn
- $3.02bn
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Knight Therapeutics Submits Crexont® (Carbidopa And Levodopa) Extended-Release Capsules In Mexico
Amneal Pharmaceuticals' Q2 revenue misses estimates
Amneal Pharmaceuticals Inc expected to post earnings of 18 cents a share - Earnings Preview
Brief: Amneal Pharmaceuticals Unit Prices $600 Mln Senior Secured Notes Due 2032 - SEC Filing
Brief: Knight Therapeutics Announces Filing Of New Drug Submission For Crexont® (Carbidopa And Levodopa) Extended-Release Capsules In Canada
Brief: Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R)
US FDA approves Amneal's self-administered migraine treatment (updated)
US FDA approves Amneal's migraine treatment
Amneal Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Amneal Pharmaceuticals Inc expected to post earnings of 15 cents a share - Earnings Preview
Brief: Amneal Announces New Data From Phase 3 Study
Brief: Amneal Announces Expanded Coverage For Crexont® To Enhance Access For Parkinson’S Disease Patients In The U.S.
Brief: Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
U.S. STOCKS ON THE MOVE-BridgeBio Pharma, NetApp, Talen Energy
U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines
Amneal Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-SoundHound AI, Duolingo, Owens & Minor
Amneal Pharma rises on strong 2025 revenue forecast, Q4 revenue beat